HIV-1 Reverse Transcriptase: A Therapeutical Target in the Spotlight

Author(s): H. C. Castro, N. I.V. Loureiro, M. Pujol-Luz, A. M.T. Souza, M. G. Albuquerque, D. O. Santos, L. M. Cabral, I. C. Frugulhetti, C. R. Rodrigues.

Journal Name: Current Medicinal Chemistry

Volume 13 , Issue 3 , 2006

Become EABM
Become Reviewer

Abstract:

Human Immunodeficiency Virus type 1 Reverse Transcriptase (HIV-1 RT) is one of the most important targets for treatment of Acquired Immune Deficiency Syndrome (AIDS). It catalyzes the reverse transcription of HIV-RNA into a double stranded DNA, and the knowledge of its substrate specificity and catalytic mechanism has guided the development of several inhibitors widely used on current HIV/AIDS therapy. However, mutations in HIV-1 RT structure can lead to the emergence of drug-resistant virus strains. The goal of this review is to summarize relevant structural features of HIV-1 RT and its inhibitors in such a way that this cost-effective target in the development of new antiretroviral drugs is particularly highlighted.

Keywords: Reverse transcriptase, nucleoside, nucleotide, non-nucleoside, DNA, RNA, antiretroviral, AIDS

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 13
ISSUE: 3
Year: 2006
Page: [313 - 324]
Pages: 12
DOI: 10.2174/092986706775476089
Price: $58

Article Metrics

PDF: 9